During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 2.77 million, with the beta value of the company hitting 2.21. The 52-week high for the ADAP share is $2.05, that puts it down -192.86 from that peak though still a striking 40.0% gain since the share price plummeted to a 52-week low of $0.42. The company’s market capitalization is $178.17M, and the average intraday trading volume over the past 10 days was 1.24 million shares, and the average trade volume was 1.54 million shares over the past three months.
Adaptimmune Therapeutics Plc ADR (ADAP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.80. ADAP has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.13.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Adaptimmune Therapeutics Plc ADR (ADAP) registered a -1.09% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.09% in intraday trading to $0.70, hitting a weekly high. The stock’s 5-day price performance is -11.22%, and it has moved by -24.38% in 30 days. Based on these gigs, the overall price performance for the year is 25.55%. The short interest in Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) is 5.56 million shares and it means that shorts have 5.0 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 76.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $4 respectively. As a result, ADAP is trading at a discount of -471.43% off the target high and -42.86% off the low.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Statistics show that Adaptimmune Therapeutics Plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Adaptimmune Therapeutics Plc ADR (ADAP) shares have gone down -42.41% during the last six months, with a year-to-date growth rate more than the industry average at 61.90% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 35.00% this quarter and then jump 54.20% in the quarter after that. In the rating firms’ projections, revenue will increase 174.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 11.17M as predicted by 8 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 12.28M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.32M and 231k respectively. In this case, analysts expect current quarter sales to grow by 52.60% and then jump by 5,216.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.30%. While earnings are projected to return 45.72% in 2024, the next five years will return 1.00% per annum.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Adaptimmune Therapeutics Plc ADR insiders own 0.38% of total outstanding shares while institutional holders control 61.19%, with the float percentage being 61.42%. MATRIX CAPITAL MANAGEMENT COMPANY, LP is the largest shareholder of the company, while 93.0 institutions own stock in it. As of 2024-06-30, the company held over 38.97 million shares (or 16.1135% of all shares), a total value of $38.0 million in shares.
The next largest institutional holding, with 27.4 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 11.3299% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $26.72 million.
